 |
|
|
| |
The HBV capsid assembly modulator JNJ-379 is a potent inhibitor of viral replication across full length genotype A-H clinical isolates in vitro
|
| |
| |
Reported by Jules Levin
AASLD 2017 Oct 20-24 Wash DC
AASLD: Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Non-cirrhotic, Treatment-naïve Patients with Chronic Hepatitis B. - (11/01/17)
Jan Martin Berke1, Thierry Verbinnen1, Ying Tan2, Pascale Dehertogh1, Karen Vergauwen1, Koen Vandyck1, Oliver Lenz1;
1Janssen Research & Development, Beerse, Belgium;
2Janssen China Research & Development Center, Shanghai,
China
|
| |
|
|
|
|
|
